AR101483A1 - COMPUESTOS DE TIAZIN-2-AMINA FUSIONADOS CON CICLOPROPILO COMO INHIBIDORES DE b-SECRETASA Y MÉTODOS DE USO - Google Patents
COMPUESTOS DE TIAZIN-2-AMINA FUSIONADOS CON CICLOPROPILO COMO INHIBIDORES DE b-SECRETASA Y MÉTODOS DE USOInfo
- Publication number
- AR101483A1 AR101483A1 ARP150102557A ARP150102557A AR101483A1 AR 101483 A1 AR101483 A1 AR 101483A1 AR P150102557 A ARP150102557 A AR P150102557A AR P150102557 A ARP150102557 A AR P150102557A AR 101483 A1 AR101483 A1 AR 101483A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocyclyl
- ring
- alkenyl
- chc
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- XIPUIGPNIDKXJU-UHFFFAOYSA-N [CH]1CC1 Chemical class [CH]1CC1 XIPUIGPNIDKXJU-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 30
- -1 cyclopropylmethoxy, 2-propynyloxy, 2-butyloxy, 3-butyloxy Chemical group 0.000 abstract 13
- 125000005842 heteroatom Chemical group 0.000 abstract 12
- 229910052760 oxygen Inorganic materials 0.000 abstract 9
- 125000000623 heterocyclic group Chemical group 0.000 abstract 7
- 125000001424 substituent group Chemical group 0.000 abstract 7
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 4
- 125000002950 monocyclic group Chemical group 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000001188 haloalkyl group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 3
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 abstract 3
- 125000002619 bicyclic group Chemical group 0.000 abstract 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 2
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 abstract 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 2
- 125000002757 morpholinyl group Chemical group 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 2
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 2
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 abstract 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 abstract 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 abstract 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 abstract 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 abstract 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 abstract 1
- 125000001786 isothiazolyl group Chemical group 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 125000004274 oxetan-2-yl group Chemical group [H]C1([H])OC([H])(*)C1([H])[H] 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
- 125000001113 thiadiazolyl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
- C07D279/08—1,3-Thiazines; Hydrogenated 1,3-thiazines condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1), o un estereoisómero, tautómero, hidrato, solvato o sal farmacéuticamente aceptable del mismo, caracterizado porque A⁴ es CR⁴ o N; A⁵ es CR⁵ o N; A⁶ es CR⁶ o N; A⁸ es CR⁸ o N, con la condición de que no más de dos de A⁴, A⁵, A⁶ y A⁸ es N; cada uno de Rᵃ y Rᵇ, independientemente, es H, F, Cl, alquilo-C₁₋₆, alquenilo-C₂₋₄, alquinilo-C₂₋₄, CN, -CH₂O-alquilo-C₁₋₆, -O-alquilo-C₁₋₆, -S(O)ₒ-alquilo-C₁₋₆, -NH-alquilo-C₁₋₆ o -C(O)alquilo-C₁₋₆, en donde cada uno de la porción alquilo-C₁₋₆, alquenilo-C₂₋₄, alquinilo-C₂₋₄, y alquilo-C₁₋₆ de -CH₂O-alquilo-C₁₋₆, -O-alquilo-C₁₋₆, -S(O)ₒ-alquilo-C₁₋₆, -NH-alquilo-C₁₋₆ y -C(O)alquilo-C₁₋₆ están opcionalmente sustituidas con 1 - 4 sustituyentes de F, oxo u OH; R¹ y cualquiera de Rᵃ o Rᵇ puede unirse opcionalmente para formar un anillo saturado de 5 miembros que incluye un heteroátomo S; R¹ es H, F, Cl, alquilo-C₁₋₆, alquenilo-C₂₋₄, alquinilo-C₂₋₄,CN, -CH₂O-alquilo-C₁₋₆, -O-alquilo-C₁₋₆, -S(O)ₒ-alquilo-C₁₋₆, -NH-alquilo-C₁₋₆, -alquilo-C₁₋₆-NH₂, -alquilo-C₁₋₆-NH-alquilo-C₁₋₆, -alquilo-C₁₋₆-NHC(O)O-alquilo-C₁₋₆, -alquilo-C₁₋₆-NHC(O)NH-alquilo-C₁₋₆, -alquilo-C₁₋₆-NHC(O)alquilo-C₁₋₆, -C(O)NH₂, -CH=CHC(O)NH₂, -CH=CHC(O)NH-alquilo-C₁₋₆, -CH=CHC(O)N(alquilo-C₁₋₆)₂, -CH=CHC(O)NH-alquilo-C₁₋₆-O-alquilo-C₁₋₆, -CH=CHC(O)-heterociclilo, CH=C(CH₃)C(O)-heterociclilo, -CH=CHC(O)₂H, -CH=CHC(O)O-alquilo-C₁₋₆, -CH=CHCH₂OH, alquilo-C₁₋₆-C(O)NH-alquilo-C₁₋₆, alquilo-C₁₋₆-C(O)N(alquilo-C₁₋₆)₂, -C(O)alquilo-C₁₋₆, -C(O)alquenilo-C₁₋₆, -C(O)OH, -C(O)O-alquilo-C₁₋₆, -C(O)NH-alquilo-C₁₋₆, -C(O)N(alquilo-C₁₋₆)₂, -C(O)NH-cicloalquilo-C₃₋₆, -C(O)NHO-alquilo-C₁₋₆, -C(O)N(alquilo-C₁₋₆)O-alquilo-C₁₋₆, -C(O)-heterociclilo, -CH₂-heteroarilo, o heteroarilo, en donde los grupos heterociclilo de los grupos -CH=CHC(O)-heterociclilo, -CH=C(CH₃)C(O)-heterociclilo, y -C(O)-heterociclilo son anillos monocíclicos de 3, 4, 5, 6 ó 7 miembros completamente o parcialmente insaturados que incluye 1 heteroátomo seleccionado de N, O, o S si el anillo es un anillo de 3 miembros, que incluye 1 ó 2 heteroátomos independientemente seleccionados de N, O, o S si el anillo es un anillo de 4 ó 5 miembros, e incluye 1, 2, ó 3 heteroátomos independientemente seleccionados de N, O, o S si el anillo es un anillo de 6 ó 7 miembros, en donde el grupo heteroarilo de los grupos -CH₂-heteroarilo y heteroarilo es un anillo de 5 ó 6 que incluye 1, 2, 3 ó 4 heteroátomos seleccionados de N ,O, o S, en donde cada una de la porción alquilo-C₁₋₆, alquenilo-C₂₋₄, alquinilo-C₂₋₄ y cicloalquilo-C₃₋₆ de los grupos alquilo-C₁₋₆, alquenilo-C₂₋₄, alquinilo-C₂₋₄, -CH₂O-alquilo-C₁₋₆, -O-alquilo-C₁₋₆, -S(O)ₒ-alquilo-C₁₋₆, NH-alquilo-C₁₋₆, C₍O₎ₐₗqᵘⁱₗₒ₋C₁₋₆, -C(O)alquenilo-C₁₋₆, -C(O)NH-alquilo-C₁₋₆, -C(O)N(alquilo-C₁₋₆)₂, -C(O)NH-cicloalquilo-C₃₋₆, -CH=CHC(O)NH-alquilo-C₁₋₆ y alquilo-C₁₋₆-C(O)NH-alquilo-C₁₋₆, están opcionalmente sustituidas con 1 - 4 sustituyentes de F, CN, metilo, oxo u OH, y además en donde cada uno de los grupos heterociclilo de los grupos -CH=CHC(O)-heterociclilo, -CH=C(CH₃)C(O)-heterociclilo, y -C(O)heterociclilo está opcionalmente sustituido con 1 - 4 sustituyentes independientemente seleccionados de F, metilo, OH, o OCH₃ y además en donde cada uno de los grupos heteroarilo de los grupos -CH₂-heteroarilo y heteroarilo está opcionalmente sustituido con 1 - 3 sustituyentes independientemente seleccionados de halo, metilo, u OH; R² es H, F, Cl, alquilo-C₁₋₆, alquenilo-C₂₋₄, alquinilo-C₂₋₄, CN, -CH₂O-alquilo-C₁₋₆, -O-alquilo-C₁₋₆, -S(O)ₒ-alquilo-C₁₋₆, -NH-alquilo-C₁₋₆, -C(O)NH₂, -CH=CHC(O)NH-alquilo-C₁₋₆, -CH=CHC(O)₂H, CH=CHCH₂OH, alquilo-C₁₋₆-C(O)NH-alquilo-C₁₋₆, -C(O)alquilo-C₁₋₆ o -C(O)alquenilo-C₁₋₆, en donde cada una de la porción alquilo-C₁₋₆, alquenilo-C₂₋₄, alquinilo-C₂₋₄, y alquilo-C₁₋₆ de -CH₂O-alquilo-C₁₋₆, -O-alquilo-C₁₋₆, -S(O)ₒ-alquilo-C₁₋₆, -NH-alquilo-C₁₋₆, C₍O₎ₐₗqᵘⁱₗₒ₋C₁₋₆, -C(O)alquenilo-C₁₋₆, -CH=CHC(O)NH-alquilo-C₁₋₆ y alquilo-C₁₋₆-C(O)NH-alquilo-C₁₋₆, está opcionalmente sustituida con 1 - 4 sustituyentes de F, CN, oxo u OH; R³ es alquilo-C₁₋₄, CH₂O-alquilo-C₁₋₄, CH₂OH, haloalquilo-C₁₋₄ o ciclopropilo, en donde cada uno del alquilo-C₁₋₄, CH₂O-alquilo-C₁₋₄, haloalquilo-C₁₋₄ y ciclopropilo está opcionalmente sustituido con 1 - 4 átomos F; cada uno de R⁴, R⁵, R⁶ y R⁸, independientemente, es H halo, haloalquilo, haloalcoxilo, alquilo-C₁₋₄ CN, OH, O-alquilo-C₁₋₄, S(O)ₒ-alquilo-C₁₋₄, NH-alquilo-C₁₋₄, C₍O₎ₐₗqᵘⁱₗₒ₋C₁₋₄, C₍O₎O₋ₐₗqᵘⁱₗₒ₋C₁₋₄, o CH₂OH; R⁷ es -NH-R⁹ o-NH-C(=O)-R⁹; R⁹ es un anillo monocíclico de 3, 4, 5, 6 ó 7 miembros o bicíclico de 8, 9 ó 10 miembros completamente o parcialmente insaturado formado de átomos de carbono, el anillo incluye opcionalmente 1 - 4 heteroátomos si es monocíclico o 1 - 5 heteroátomos si es bicíclico, los heteroátomos seleccionados de O, N o S, en donde el anillo está opcionalmente sustituido, independientemente, con 1 - 5 sustituyentes de R¹⁰; cada R¹⁰, independientemente, es H, halo, haloalquilo, CN, OH, NO₂, NH₂, SF₅, acetilo, -C(O)NH-alquilo-C₁₋₆, -OCH₂C(O)NH-alquilo-C₁₋₆, -OCH₂C(O)N(alquilo-C₁₋₆)₂, -OCH₂CH₂-pirolidinonilo, oxo, ciclopropilmetoxi, 2-propiniloxi, 2-butiniloxi, 3-butiniloxi, 3-pentiniloxi, 2-pentiloxi, alquilo-C₁₋₆, alquenilo-C₂₋₆, alquinilo-C₂₋₆, cicloalquilo-C₃₋₆, alquilamino-C₁₋₆, dialquilamino-C₁₋₆, alcoxilo-C₁₋₆, -O-alquenilo-C₂₋₆, tioalcoxilo-C₁₋₆, -OCH₂-cicloalquilo-C₃₋₆, morfolinilo, pirazolilo, isoxazolilo, dihidropiranilo, pirrolilo, pirrolidinilo, tetrahidropirrolilo, piperazinilo, oxetan-3-ilo, imidazo-piridinilo, dioxolilo, -O-heterociclilo, o -OCH₂-heteroarilo, en donde el heterociclilo del grupo -O-heterociclilo es un anillo saturado monocíclico de 3, 4, 5, 6 ó 7 miembros que incluye 1 heteroátomo seleccionados de N, O, o S si el anillo heterociclilo es un anillo de 3 miembros, que incluye 1 ó 2 heteroátomos independientemente seleccionados de N, O, o S si el anillo heterociclilo es un anillo de 4 ó 5 miembros, e incluye 1, 2, ó 3 heteroátomos independientemente seleccionados de N, O, o S si el anillo heterociclilo es un anillo de 6 ó 7 miembros en donde el grupo heteroarilo del grupo -OCH₂-heteroarilo es un anillo de 5 ó 6 miembros que incluye 1, 2, 3, ó 4 heteroátomos seleccionados de N, O, o S, y además en donde cada uno del ciclopropilmetoxi, 2-propiniloxi, 2-butiniloxi, 2-pentiloxi, alquilo-C₁₋₆, alquenilo-C₂₋₆, alquinilo-C₂₋₆, cicloalquilo-C₃₋₆, alquilamino-C₁₋₆, dialquilamino-C₁₋₆, alcoxilo-C₁₋₆, tioalcoxilo-C₁₋₆, -OCH₂-cicloalquilo-C₃₋₆, morfolinilo, pirazolilo, isoxazolilo, dihidropiranilo, pirrolidinilo, oxetan-3-ilo, dioxolilo o -OCH₂-heteroarilo está opcionalmente sustituido independientemente con 1 - 5 sustituyentes de F, Cl, Br, CN, NO₂, NH₂, OH, oxo, CF₃, CHF₂, CH₂F, metilo, metoxi, etilo, etoxi, CH₂CF₃, CH₂CHF₂, propilo, propoxi, isopropilo, isopropoxi, ciclopropilo, butilo, butoxilo, ciclobutilo, isobutoxi, tert-butoxi, isobutilo, sec-butilo, tert-butilo, ciclopentilo, ciclohexilo, fenilo, alquilamino-C₁₋₃, dialquilamino-C₁₋₃, tioalcoxilo-C₁₋₃, oxazolilo, isoxazolilo, tiazolilo, isotiazolilo, tiadiazolilo, tienilo, furilo, pirrolilo, tetrahidropiranilo, tetrahidropirrolilo, oxetan-2-ilo, u oxetan-3-ilo; y el subíndice o se selecciona de 0, 1, ó 2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462035269P | 2014-08-08 | 2014-08-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR101483A1 true AR101483A1 (es) | 2016-12-21 |
Family
ID=54150645
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150102557A AR101483A1 (es) | 2014-08-08 | 2015-08-07 | COMPUESTOS DE TIAZIN-2-AMINA FUSIONADOS CON CICLOPROPILO COMO INHIBIDORES DE b-SECRETASA Y MÉTODOS DE USO |
Country Status (12)
Country | Link |
---|---|
US (2) | US9550762B2 (es) |
EP (1) | EP3177618A1 (es) |
JP (1) | JP6576433B2 (es) |
CN (1) | CN106795147B (es) |
AR (1) | AR101483A1 (es) |
AU (1) | AU2015301028B2 (es) |
CA (1) | CA2957544C (es) |
JO (1) | JO3569B1 (es) |
MX (1) | MX2017001794A (es) |
TW (1) | TWI614250B (es) |
UY (1) | UY36263A (es) |
WO (1) | WO2016022724A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112015021336A2 (pt) | 2013-03-08 | 2017-07-18 | Amgen Inc | compostos 1,3-oxazin-2-amina fundidos ciclopropil perfluorados como inibidores de beta-secretase e métodos de uso |
EP3177618A1 (en) | 2014-08-08 | 2017-06-14 | Amgen Inc. | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
US10246429B2 (en) | 2015-08-06 | 2019-04-02 | Amgen Inc. | Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
EP3555085B1 (en) | 2016-12-15 | 2020-12-02 | Amgen Inc. | Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use |
ES2910791T3 (es) | 2016-12-15 | 2022-05-13 | Amgen Inc | Derivados de tiazina como inhibidores de beta-secretasa y métodos de uso |
CA3047290A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use |
JP7148518B2 (ja) | 2016-12-15 | 2022-10-05 | アムジエン・インコーポレーテツド | β-セクレターゼ阻害剤としての二環式チアジンおよびオキサジン誘導体ならびに使用方法 |
MA52722A (fr) | 2016-12-15 | 2021-04-14 | Amgen Inc | Dérivés d'oxazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation |
WO2018224455A1 (en) | 2017-06-07 | 2018-12-13 | Basf Se | Substituted cyclopropyl derivatives |
CN113087669B (zh) * | 2019-12-23 | 2023-11-17 | 南京药石科技股份有限公司 | 一种4-氰基-5-溴嘧啶的制备方法 |
CN115684413A (zh) * | 2022-11-01 | 2023-02-03 | 重庆市涪陵食品药品检验所 | 一种硫酸羟氯喹中硫酸二甲酯和硫酸二乙酯的检测方法 |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5441870A (en) | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
SI9300303A (en) | 1993-06-08 | 1994-12-31 | Krka Tovarna Zdravil | Process for isolation of hypolipemic effective substance |
US5942400A (en) | 1995-06-07 | 1999-08-24 | Elan Pharmaceuticals, Inc. | Assays for detecting β-secretase |
KR20070013361A (ko) | 1998-09-24 | 2007-01-30 | 파마시아 앤드 업존 캄파니 엘엘씨 | 알츠하이머병 세크레타제 |
US20040234976A1 (en) | 1998-09-24 | 2004-11-25 | Gurney Mark E. | Alzheimer's disease secretase, app substrates therefor, and uses therefor |
US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
SI1699455T1 (sl) | 2003-12-15 | 2013-10-30 | Merck Sharp & Dohme Corp. | Heterocikliäśni aspartil proteazni inhibitorji |
US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US20090264415A2 (en) | 2004-12-30 | 2009-10-22 | Steven De Jonghe | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment |
CA2628074C (en) | 2005-10-25 | 2014-01-14 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivative |
WO2008133273A1 (ja) | 2007-04-24 | 2008-11-06 | Shionogi & Co., Ltd. | アルツハイマー症治療用医薬組成物 |
KR20100017255A (ko) | 2007-04-24 | 2010-02-16 | 시오노기 앤드 컴파니, 리미티드 | 환식기로 치환된 아미노다이하이드로싸이아진 유도체 |
WO2009016460A2 (en) | 2007-08-01 | 2009-02-05 | Pfizer Inc. | Pyrazole compounds and their use as raf inhibitors |
CA2711655C (en) | 2008-01-18 | 2013-03-05 | Eisai R&D Management Co., Ltd. | Condensed aminodihydrothiazine derivative |
TWI431004B (zh) | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Bace抑制劑 |
US8637504B2 (en) | 2008-06-13 | 2014-01-28 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
WO2010013302A1 (ja) | 2008-07-28 | 2010-02-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スピロアミノジヒドロチアジン誘導体 |
CA2731209A1 (en) | 2008-07-28 | 2010-02-04 | Eisai R&D Management Co., Ltd. | Spiroaminodihydrothiazine derivatives |
US8461160B2 (en) | 2009-05-08 | 2013-06-11 | Hoffmann-La Roche, Inc. | Dihydropyrimidinones |
AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
GB0912778D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
US8188079B2 (en) | 2009-08-19 | 2012-05-29 | Hoffman-La Roche Inc. | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines |
US20110065695A1 (en) | 2009-09-11 | 2011-03-17 | Jeremy Beauchamp | Use of aminodihydrothiazines for the treatment or prevention of diabetes |
UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
US20120238557A1 (en) | 2009-11-13 | 2012-09-20 | Shionogi & Co., Ltd. | Aminothiazine or aminooxazine derivative having amino linker |
JP5554346B2 (ja) | 2009-12-09 | 2014-07-23 | 塩野義製薬株式会社 | 含硫黄複素環誘導体を含有するアルツハイマー症の治療用または予防用医薬組成物 |
EP2514747A4 (en) * | 2009-12-09 | 2013-05-08 | Shionogi & Co | SUBSTITUTED AMINOTHIAZINE DERIVATIVE |
US7964594B1 (en) | 2009-12-10 | 2011-06-21 | Hoffmann-La Roche Inc. | Amino oxazine derivatives |
US8999980B2 (en) | 2009-12-11 | 2015-04-07 | Shionogi & Co., Ltd. | Oxazine derivatives |
US20120245155A1 (en) | 2009-12-11 | 2012-09-27 | Shionogi & Co., Ltd. | Fused heterocyclic compound having amino group |
UA103272C2 (uk) | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
CN103108927B (zh) | 2010-09-24 | 2015-12-16 | 可乐丽股份有限公司 | 糊料和将其涂膜作为电解质膜、电极膜的高分子换能器 |
MX2013008111A (es) | 2011-01-12 | 2013-10-30 | Novartis Ag | Derivados de oxazina y su uso en el tratamiento de transtornos neurologicos. |
EA201391033A1 (ru) * | 2011-01-13 | 2014-01-30 | Новартис Аг | Ингибиторы bace-2 для лечения метаболических расстройств |
US8404680B2 (en) | 2011-02-08 | 2013-03-26 | Hoffmann-La Roche Inc. | N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors |
US9221839B2 (en) | 2011-04-07 | 2015-12-29 | Merck Sharp & Dohme Corp. | C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
US8754075B2 (en) | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
EP2703399A4 (en) | 2011-04-26 | 2014-10-15 | Shionogi & Co | OXAZINE DERIVATIVE AND BACE-1 HEMMER THEREOF |
JPWO2012147762A1 (ja) * | 2011-04-26 | 2014-07-28 | 塩野義製薬株式会社 | ピリジン誘導体およびそれを含有するbace1阻害剤 |
EP2517898A1 (de) | 2011-04-29 | 2012-10-31 | Lanxess Deutschland GmbH | Kieselsäurehaltige Kautschukmischungen mit schwefelhaltigen Additiven |
US8785436B2 (en) | 2011-05-16 | 2014-07-22 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors |
US8604024B2 (en) | 2011-05-24 | 2013-12-10 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
US8598161B2 (en) | 2011-05-24 | 2013-12-03 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
US9079919B2 (en) | 2011-05-27 | 2015-07-14 | Hoffmann-La Roche Inc. | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors |
JP2012250933A (ja) | 2011-06-03 | 2012-12-20 | Shionogi & Co Ltd | オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物 |
AR086653A1 (es) | 2011-06-03 | 2014-01-15 | Bristol Myers Squibb Co | COMPUESTOS PARA LA REDUCCION DE PRODUCCION DE b-AMILOIDE |
US8987255B2 (en) | 2011-06-07 | 2015-03-24 | Hoffmann-La Roche Inc. | Halogen-alkyl-1,3 oxazines as BACE1 and/or BACE2 inhibitors |
JP5952898B2 (ja) | 2011-06-07 | 2016-07-13 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | [1,3]オキサジン |
US8927535B2 (en) * | 2011-07-06 | 2015-01-06 | Hoffman-La Roche Inc. | Cyclopropyl-fused-1,3-thiazepines as BACE1 and/or BACE2 inhibitors |
AU2012298983A1 (en) | 2011-08-22 | 2014-02-27 | Merck Sharp & Dohme Corp. | 2-spiro-substituted iminothiazines and their mono-and dioxides as BACE inhibitors, compositions and their use |
UY34278A (es) | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
WO2013030713A1 (en) | 2011-08-31 | 2013-03-07 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds |
US8476264B2 (en) | 2011-09-21 | 2013-07-02 | Hoffmann-La Roche Inc. | N-(3-(2-amino-6,6-difluoro-4,4A,5,6,7,7A-hexahydro-cyclopenta[E][1,3]oxazin-4-yl)-phenylamides as BACE1 inhibitors |
KR20140084146A (ko) | 2011-10-13 | 2014-07-04 | 노파르티스 아게 | 신규 옥사진 유도체 및 질환의 치료에서의 그의 용도 |
WO2013061962A1 (ja) | 2011-10-24 | 2013-05-02 | 武田薬品工業株式会社 | 二環性化合物 |
US9067926B2 (en) | 2012-01-26 | 2015-06-30 | Hoffmann-La Roche Inc. | Fluoromethyl-5,6-dihydro-4H-[1,3]OXAZINES |
US9493485B2 (en) | 2012-03-20 | 2016-11-15 | Imago Pharmaceuticals, Inc. | Spirocyclic dihydro-thiazine and dihydro-oxazine BACE inhibitors, and compositions and uses thereof |
DE102012005803A1 (de) | 2012-03-21 | 2013-09-26 | Wacker Neuson Produktion GmbH & Co. KG | Bohr-und/oder Schlaghammer mit belastungsabhängiger Anpassung der Schlagzahl |
CA2872154C (en) | 2012-05-04 | 2016-08-23 | Pfizer Inc. | Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds as inhibitors of app, bace1 and bace2 |
WO2013182638A1 (en) | 2012-06-08 | 2013-12-12 | H. Lundbeck A/S | 2 -aminothiazinylheteroaryls as bace1 inhibitors for the treatment alzheimer's disease |
BR112014029742A2 (pt) | 2012-06-26 | 2017-06-27 | Hoffmann La Roche | diflúor-hexa-hidrociclopentaoxazinilas e diflúor-hexa-benzo-oxazinilas como inibidores da bace1 |
GB201212871D0 (en) | 2012-07-20 | 2012-09-05 | Eisai Ltd | Novel compounds |
CA2882389A1 (en) | 2012-09-20 | 2014-03-27 | Pfizer Inc. | Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
US9556135B2 (en) * | 2012-10-12 | 2017-01-31 | Amgen, Inc. | Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use |
WO2014062549A1 (en) | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
US9416129B2 (en) | 2012-10-17 | 2016-08-16 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use |
WO2014065434A1 (en) | 2012-10-24 | 2014-05-01 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity |
LT2912041T (lt) | 2012-10-26 | 2017-03-10 | Eli Lilly And Company | Tetrahidropiroltiazino dariniai kaip bace slopikliai |
EP2931284B1 (en) | 2012-12-14 | 2017-08-23 | Merck Sharp & Dohme Corp. | Bace inhibitors of iminothiadiazine dioxides |
JP6162820B2 (ja) | 2012-12-19 | 2017-07-12 | ファイザー・インク | 炭素環式および複素環式置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
WO2014098831A1 (en) | 2012-12-19 | 2014-06-26 | Bristol-Myers Squibb Company | 4,6-diarylaminothiazines as bace1 inhibitors and their use for the reduction of beta-amyloid production |
US9365589B2 (en) | 2012-12-20 | 2016-06-14 | Merck Sharp & Dohme Corp. | C5, C6 oxacyclic-fused thiazine dioxide compounds as BACE inhibitors, compositions, and their use |
WO2014099788A1 (en) | 2012-12-21 | 2014-06-26 | Merck Sharp & Dohme Corp. | C5-spiro iminothiadiazine dioxides as bace inhibitors |
BR112015016315A2 (pt) | 2013-01-22 | 2017-07-11 | Hoffmann La Roche | fluoro-[1,3]oxazinas como inibidores de bace1 |
EP2961749B1 (en) | 2013-03-01 | 2019-10-09 | Amgen Inc. | Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
BR112015021336A2 (pt) | 2013-03-08 | 2017-07-18 | Amgen Inc | compostos 1,3-oxazin-2-amina fundidos ciclopropil perfluorados como inibidores de beta-secretase e métodos de uso |
BR112015019412A8 (pt) | 2013-04-11 | 2019-11-12 | Hoffmann La Roche | inibidores de bace1, seus usos, e composição farmacêutica |
KR20160002822A (ko) | 2013-04-26 | 2016-01-08 | 에프. 호프만-라 로슈 아게 | Bace1 억제제의 합성 |
TW201623295A (zh) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有bace1抑制活性之二氫噻及二氫衍生物 |
WO2016001266A1 (en) | 2014-07-04 | 2016-01-07 | F. Hoffmann-La Roche Ag | Fluoro-[1,3]oxazines as bace1 inhibitors |
EP3177618A1 (en) | 2014-08-08 | 2017-06-14 | Amgen Inc. | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
-
2015
- 2015-08-05 EP EP15766951.6A patent/EP3177618A1/en not_active Withdrawn
- 2015-08-05 US US14/819,256 patent/US9550762B2/en active Active
- 2015-08-05 MX MX2017001794A patent/MX2017001794A/es unknown
- 2015-08-05 WO PCT/US2015/043868 patent/WO2016022724A1/en active Application Filing
- 2015-08-05 CN CN201580054674.2A patent/CN106795147B/zh active Active
- 2015-08-05 CA CA2957544A patent/CA2957544C/en active Active
- 2015-08-05 AU AU2015301028A patent/AU2015301028B2/en active Active
- 2015-08-05 JP JP2017506879A patent/JP6576433B2/ja active Active
- 2015-08-07 AR ARP150102557A patent/AR101483A1/es unknown
- 2015-08-07 TW TW104125848A patent/TWI614250B/zh active
- 2015-08-07 UY UY0001036263A patent/UY36263A/es not_active Application Discontinuation
- 2015-08-09 JO JOP/2015/0190A patent/JO3569B1/ar active
-
2016
- 2016-11-17 US US15/354,877 patent/US20170267673A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2957544C (en) | 2023-01-24 |
JP6576433B2 (ja) | 2019-09-18 |
JP2017523223A (ja) | 2017-08-17 |
AU2015301028B2 (en) | 2019-09-26 |
CN106795147B (zh) | 2020-09-22 |
TW201619154A (zh) | 2016-06-01 |
WO2016022724A1 (en) | 2016-02-11 |
CN106795147A (zh) | 2017-05-31 |
UY36263A (es) | 2016-02-29 |
AU2015301028A1 (en) | 2017-03-09 |
CA2957544A1 (en) | 2016-02-11 |
TWI614250B (zh) | 2018-02-11 |
US20170267673A1 (en) | 2017-09-21 |
US9550762B2 (en) | 2017-01-24 |
JO3569B1 (ar) | 2020-07-05 |
US20160046618A1 (en) | 2016-02-18 |
EP3177618A1 (en) | 2017-06-14 |
MX2017001794A (es) | 2017-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR101483A1 (es) | COMPUESTOS DE TIAZIN-2-AMINA FUSIONADOS CON CICLOPROPILO COMO INHIBIDORES DE b-SECRETASA Y MÉTODOS DE USO | |
AR098171A1 (es) | Piridinilimidazolonas como herbicidas | |
PE20181093A1 (es) | Compuestos heterociclicos y usos de los mismos | |
AR102948A1 (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo como inhibidores del receptor p2x3 | |
AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
AR103251A1 (es) | Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico | |
AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
AR112392A1 (es) | Compuesto tricíclico de pirazol, su uso para fabricar un medicamento y composición farmaceutica que lo comprende | |
CL2018000697A1 (es) | Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue. | |
AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
AR113826A1 (es) | Indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb) | |
AR106100A1 (es) | Compuestos bicíclicos como inhibidores duales atx / ca | |
AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
AR103266A1 (es) | Compuestos cíclicos sustituidos con un sistema de anillos condensado para combatir plagas de invertebrados | |
AR100776A1 (es) | Compuestos herbicidas | |
EA201890361A1 (ru) | Производные 5-(n-бензил-тетрагидроизохинолин-6-ил)пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека | |
AR100440A1 (es) | Derivados de carboxamida como inhibidores selectivos de smurf1 | |
BR112016012469A2 (pt) | Isopropil triazolo piridina, seus usos, seu processo de preparação e seus intermediários, composição farmacêutica | |
AR095059A1 (es) | Compuestos herbicidas | |
AR096023A1 (es) | Amidas fungicidas | |
AR109108A1 (es) | Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2 | |
AR095093A1 (es) | COMPUESTOS DE SULFONA MULTICÍCLICOS FUSIONADOS COMO INHIBIDORES DE LA b-SECRETASA Y MÉTODOS PARA SU USO | |
AR102825A1 (es) | Derivados heterocíclicos de amida activos como plaguicidas con sustituyentes que contienen azufre | |
AR097157A1 (es) | COMPUESTOS DE DIÓXIDO DE AMINO TIAZINA BICÍCLICOS PUNTEADOS COMO INHIBIDORES DE b-SECRETASA Y SUS MÉTODOS DE USO | |
AR109387A1 (es) | INHIBIDORES DEL FACTOR XIa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |